The study concludes that TIL therapy, specifically targeting p53 mutations, could be a promising strategy in advanced cancer treatment. However, challenges such as low frequency and limited persistence of tumor-specific neoantigen-reactive TILs, like p53 mutations, need to be addressed to enhance therapy efficacy. This evidence concerns the gene TP53 and neoplasm.